Biomarkers Predicting a Need for Intensive Treatment in Patients with Early Arthritis

González‐Álvaro, Isidoro; Ortiz, Ana M.; Seoane, Iria V.; García‐Vicuña, Rosario; Martı́nez, Carmen; Gomariz, Rosa P.

doi:10.2174/1381612820666140825123104

Cited by 24 publications

(26 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies are being done on different types of connective tissue collagen, to better understand and reduce RA disease activity. Lastly, with the scientific advancements and enhanced understanding of the molecular mechanisms, newer and better treatment options should become available in the near future [50-55]. …”

Section: Other Therapiesmentioning

confidence: 99%

Rheumatoid Arthritis: A Brief Overview of the Treatment

et al. 2018

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease, affecting the joints with varying severity among patients. The risk factors include age, gender, genetics, and environmental exposure (cigarette smoking, air pollutants, and occupational). Many complications can follow, such as permanent joint damage requiring arthroplasty, rheumatoid vasculitis, and Felty syndrome requiring splenectomy if it remains unaddressed. As there is no cure for RA, the treatment goals are to reduce the pain and stop/slow further damage. Here, we present a brief summary of various past and present treatment modalities to address the complications associated with RA.

show abstract

Section: Other Therapiesmentioning

confidence: 99%

Rheumatoid Arthritis: A Brief Overview of the Treatment

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Identifying biomarkers predictive of treatment response offers an opportunity to improve clinical decisions about which treatment to recommend in patients and could ultimately lead to better patient outcomes [3]. Currently, methotrexate is typically prescribed as the first choice DMARD to treat RA either as mono or combined therapy but by two years, up to 45 % of patients have moved to other therapies [4]; patients who fail to respond to methotrexate can be prescribed another DMARD, or a biologic drug, which modulates the immune system and/or inflammatory pathways to alleviate disease.…”

Section: Introductionmentioning

confidence: 99%

Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study

Kumar

Peters

Barton

2016

BMC Musculoskelet Disord

View full text Add to dashboard Cite

BackgroundRheumatoid arthritis (RA) is a long term condition that requires early treatment to control symptoms and improve long-term outcomes. Lack of response to RA treatments is not only a waste of healthcare resources, but also causes disability and distress to patients. Identifying biomarkers predictive of treatment response offers an opportunity to improve clinical decisions about which treatment to recommend in patients and could ultimately lead to better patient outcomes. The aim of this study was to explore the understanding of and factors affecting Rheumatoid Arthritis (RA) patients’ decisions around predictive treatment testing.MethodsA qualitative study was conducted with a purposive sample of 16 patients with RA from three major UK cities. Four focus groups explored patient perceptions of the use of biomarker tests to predict response to treatments. Interviews were audio-recorded, transcribed verbatim and analysed using thematic analysis by three researchers.ResultsData were organised within three interlinking themes: [1] Perceptions of predictive tests and patient preference of tests; [2] Utility of the test to manage expectations; [3] The influence of the disease duration on take up of predictive testing. During consultations for predictive testing, patients felt they would need, first, careful explanations detailing the consequences of untreated RA and delayed treatment response and, second, support to balance the risks of tests, which might be invasive and/or only moderately accurate, with the potential benefits of better management of symptoms.ConclusionsThis study provides important insights into predictive testing. Besides supporting clinical decision making, the development of predictive testing in RA is largely supported by patients. Developing strategies which communicate risk information about predictive testing effectively while reducing the psychological burden associated with this information will be essential to maximise uptake.

show abstract

“…1,2 . Identifying biomarkers predictive of treatment response offers an opportunity to improve clinical decisions about which treatment to recommend in patients 3 . For this, we should take into account patients' perspective of these tests and that requires an understanding of the range of effects that predictive testing can have on RA patients.…”

Section: Discussionmentioning

confidence: 99%

“…[13 female, age ranges: 26-80 years old, disease duration: 3-34 years]. Five interlinking themes influenced how RA patients would make decisions about predictive tests: [1] Perceptions surrounding the use of synovial biopsy and/or blood tests: [2] Perceptions surrounding the use of synovial biopsy vs blood test: [3] Utility of the test to manage expectations: [4] The stages of illness on decision making for predictive testing: [5] Understanding the predictive tests in clinic. Conclusions: Besides supporting clinical decision making, the development of predictive testing in RA is supported by patients.…”

Section: Discussionmentioning

confidence: 99%

AB1088-HPR Intense Emotions and Mood States Influence The Disease Activity and Quality of Life in Rheumatoid Arthritis

Udrea¹,

Niculescu²,

Stefan

2016

Ann Rheum Dis

View full text Add to dashboard Cite

BackgroundResearchers began to unravel the complex interactions between mental and physical health. Some particular feelings (intense emotions) triggered by a chronic disease as rheumatoid arthritis (RA) can induce different types of mood, such as generalized anxiety or stress with possible implications on disease activity and the quality of life HRQoL.ObjectivesThe aims of the study were to investigate the associations of the intense positive and negative feelings, level of negative affect with aspects of HRQoL and disease activity in RA patients.Methods50 patients with RA who met the 2010 ACR/EULAR classification criteria for RA but without an emotional disorder or mental health diagnosis were enrolled in this study. Disease activity was assessed with DAS 28-CRP, and visual analog scale (VAS) for pain. The study used: the Short Form-36 (SF-36), general questionnaire for assessment HRQoL, Depression, Anxiety and Stress Scale (DASS-21R) to measure the three related negative emotional states of depression, anxiety and stress. Both of them were Romanian validated versions of the original questionnaires1,2. Information about positive and negative feelings was collected by open- questions. Pearson correlations were used to verify associations between normally distributed variables, One Way Anova to compare means for different intense feelings and linear regression to identify the predictors for DAS 28-CRP, and components of HRQoL.ResultsThe response rate was 74%. The study included 89% females, mean age 53.4 ± 13.3 years, mean duration of the disease 10.5 ± 7.1 years, DAS 28-CRP score 4.2 ± 1.1, mean pain score 4.9±2 cm. We found a moderate negative correlation between total DASS-21 scale and mental component score (MCS) of HRQoL (R=-0.428;p=0.007*). Intense feelings in the last month: positive, negative, positive and negative, without feelings are correlate with DAS28 CRP – F (3,35)=5.931, p=0.00. We identified that predictors for DAS 28 CRP are MCS with F(1,37)=13.176, p=0.00 with R2=0.263, and PCS with F(1,37)=16.371, p=0.00 with R2=0.306. The significant predictors for MCS were total DASS-21R score F(1,36)=8.062, p=0.00 with R2=0,183, depression score F(1,37)=4.139, p=0.04 with R2=0,317, anxiety score F(1,36)=6.961, p=0.01 with R2=0,162 and stress score F(1,37)=4.928, p=0.03 with R2=0,118. For PCS the only significant predictor we found was DAS-CRP F(1,37)=16,279, p=0.00 with R2=0,306.ConclusionsThe negative affect doesn't impact the disease activity or pain in RA but it influences the mental health component of HRQoL. The experienced intense emotions (feelings) are very important for mental health and also for disease activity in RA and could represent a starting point for further research in orther to avoid bias in clinical trials.ReferencesMihaila V., et al.: General population norms for Romania using the Short Form 36 health survey (SF-36). Quality of Life Newsletter.2001;26:17–18Lovibond JH, Lovibond PF, Perte A, Albu M. Manual pentru Scala de depresie, anxietate si stress-DASS. Adaptarea si standardizarea pe...

show abstract

Biomarkers Predicting a Need for Intensive Treatment in Patients with Early Arthritis

Cited by 24 publications

References 93 publications

Rheumatoid Arthritis: A Brief Overview of the Treatment

Rheumatoid Arthritis: A Brief Overview of the Treatment

Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study

AB1088-HPR Intense Emotions and Mood States Influence The Disease Activity and Quality of Life in Rheumatoid Arthritis

Contact Info

Product

Resources

About